Catena Biosciences
Using protein coupling to build new therapies
Berkeley, United States · Founded 2020 · $2.4M raised
- Headquarters
- Berkeley, California
- Employees
- 1–10
- Founded
- 2020
- Website
- catenabiosciences.com
- Total Funding
- $2.4M
- Last Round
- $2.4M SeedMay 2024
- Rounds
- 3
About
Catena’s technology lets us attach any two proteins together using an enzyme and the native amino acids tyrosine and cysteine within target proteins. It is a true platform technology because it enables the joining of any two soluble proteins together with minimal engineering and without restrictions due to protein size or complexity. Our work has already been used to modify cancer specific antibodies, CRISPR proteins and even cell surfaces. Our ability to produce modular protein therapeutics in a fraction of the time allows for true library creation across the therapeutics spectrum from oncology, vaccines, inflammatory disease and beyond.
Summary
Catena Biosciences is a Biotech company based in Berkeley, United States, founded in 2020. It has raised $2.4M in total across 3 rounds, most recently a $2.4M Seed round in May 2024. Investors include California Innovation Fund, Civilization Ventures and Pioneer Fund.
Tech & App Stack
5 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
May 2024
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
Global contract research organization providing comprehensive drug development and laboratory ser...
